Diabetes is a common disease characterized by impaired glycemic control in the
body. We used a retrospective, chart review study design to collect the A1c
readings in patients using Dapagliflozin 10mg. The total sample size was 107
participants. 57 participants were on Dapagliflozin, 33 on Semaglutide, and 17
were on a combination of Semaglutide and Dapagliflozin. Weight significantly
decreased in participants using Dapagliflozin and Semaglutide combination
(p<0.001) compared to those using Semaglutide alone (p<0.001). Additionally,
HbA1c significantly decreased among participants using Dapagliflozin and
Semaglutide (p<0.001) and those using Dapagliflozin alone (p<0.001). Even
though SGLT-2 inhibitors weakly reduce HbA1c, we have found in our study
that Dapagliflozin has significantly decreased A1c in addition to a reduction in
weight especially among females.
Keywords: Type 2 diabetes mellitus, hba1c, semaglutide, dapagliflozin, sglt-2
inhibitors